Filing summary
Issuer and period mismatch: The request metadata names Lite Strategy, Inc. and 2014 Q4, but the supplied filing is MEI Pharma, Inc. (Nasdaq: MEIP), a Form 10-K for the fiscal year ended June 30, 2016. This summary reflects the filing provided.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company developing Pracinostat, ME-401 and ME-344. It has not generated operating revenue and is focused on clinical development. The audited financial statements cover fiscal years ended June 30, 2016, 2015 and 2014; balance-sheet comparisons are as of June 30, 2016 and 2015.
Key financial metrics
| Metric | FY2016 / June 30, 2016 | Comparable period |
|---|---|---|
| Operating revenue | None reported | None reported since inception |
| Research and development expense | $13.4 million | $23.8 million in FY2015 |
| General and administrative expense | $7.6 million | $8.9 million in FY2015 |
| Net loss | $20.9 million; $0.61 per share | $32.7 million; $1.16 per share in FY2015 |
| Operating cash used | $17.9 million | $28.1 million in FY2015 |
| Cash, cash equivalents and short-term investments | $45.9 million | $63.8 million at June 30, 2015 |
| Total assets / liabilities | $47.2 million / $5.5 million | $64.8 million / $5.0 million at June 30, 2015 |
| Accumulated deficit | $177.0 million | $156.1 million at June 30, 2015 |
FY2016 investing activities provided $10.0 million, primarily reflecting investment maturities net of purchases; financing activities provided no cash. No interest-bearing debt is reported. Current assets were $46.7 million against current liabilities of $5.5 million. Operating margins are not meaningful because the company reported no operating revenue.
Material changes versus prior periods
- Net loss narrowed by $11.8 million year over year, mainly as R&D expense declined by $10.4 million and G&A expense declined by $1.3 million. Management attributed lower R&D costs primarily to reduced Pracinostat MDS trial and manufacturing spending.
- Cash and investments fell by $17.9 million from June 2015. The company reported that its June 30, 2016 resources were expected to fund operations for at least 12 months.
- In FY2015, the company raised $43.1 million net through an equity offering; there was no comparable financing cash inflow in FY2016.
- In March 2015, the Pracinostat-plus-azacitidine Phase II MDS study failed its primary endpoint of improving overall complete remission versus azacitidine alone. Discontinuations were higher in the combination arm, although exploratory analyses of patients tolerating at least four cycles favored the combination on certain measures.
Outlook, commentary, risks and unusual items
- Pracinostat: An August 2016 FDA Breakthrough Therapy Designation and agreement on a proposed Phase III design were reported for newly diagnosed AML patients aged 75 or older, or unfit for intensive chemotherapy. The Phase II AML study reported a 56% rate for CR, CRi or morphologic leukemia-free state and median overall survival of 19.1 months; these results are from a 50-patient study and are not confirmatory Phase III evidence.
- Helsinn agreement, subsequent to year-end: Helsinn received worldwide exclusive development and commercialization rights for Pracinostat and is responsible for global development and commercialization funding. MEI Pharma reported a $15 million upfront payment, a further $5 million payment upon the earlier of first patient dosed in the planned Phase III study or March 1, 2017, potential milestones of up to $444 million, and royalties. Helsinn also invested $5 million in MEI Pharma for 2,616,431 shares at $1.91 per share in August 2016.
- Other pipeline plans: ME-401’s first patient in a Phase Ib study for recurrent CLL or follicular non-Hodgkin lymphoma was expected in Q3 2016. An investigator-sponsored ME-344/bevacizumab study in HER2-negative breast cancer opened for enrollment in August 2016.
- Management expects operating losses and negative operating cash flow for the foreseeable future and may seek additional financing or partnerships. The stated 12-month cash runway was based on June 30, 2016 resources; the later Helsinn payments are additional subsequent events.
- Key risks include clinical failure or delays, regulatory approval uncertainty, reliance on third parties and Helsinn for Pracinostat, competition, and the need for additional capital and potential shareholder dilution. The filing reports no off-balance-sheet arrangements or legal proceedings.
- Contingencies include up to $75.2 million in potential S*Bio clinical, regulatory and sales-based payments; $250,000 was accrued at June 30, 2016. The office lease had $343,000 of remaining payments. The auditor issued an unqualified opinion, and management and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied filing is MEI Pharma’s FY2016 10-K, not a Lite Strategy, Inc. 2014 Q4 filing.
- Check the timing and receipt of the Helsinn payments, the terms and dilution from its equity investment, and the conditions attached to future milestones and royalties.
- Review subsequent clinical-trial updates, especially the Pracinostat Phase III program and the significance of the earlier MDS Phase II failure.
- Assess cash use and runway after year-end, including whether additional financing is needed and its potential dilutive effect.
- Evaluate the contingent S*Bio obligations and the extent to which the company depends on Helsinn and other third parties.